Collagenase Articles

US FDA approvals for Novo Nordisk’s Victoza and BioSpecific’s Xiaflex

3 February 2010

Enrollment complete in Auxilium's Ph IIb Peyronie's trial

9 February 2009

BioSpecifics Tech buys down royalties for Peyronie's disease

15 September 2008

BioSpecifics raises $1.1M in sale of shares

1 September 2008

Auxilium to resume Ph III US trials of Xiafelx

20 August 2007

British Biotech drops two drugs; starts Ph II trial

27 July 2001

Serono teams up with British Biotech

17 October 2000

No surprise as British Biotech fails again

27 September 2000

Brit Biotech losses cut, lays out new strategy

6 July 2000

Roche wavers as more drugs suffer inlate-stage clinical trials

5 April 2000

Smith & Nephew buys BASF's wound-care product, takes market lead

3 February 2000

BB's marimastat data delayed, expected early next year

22 November 1999

BB moves RA compound into development

14 October 1999

First Oral Periodontitis Treatment In USA

8 October 1998

Xenical Recommended For Approval By CPMP

16 April 1998

Biotech Promise For Rheumatoid Arthritis

26 February 1998

Rapid Advances In Wound-Healing Industry

13 January 1998

New Clinical Trials In Brief

4 December 1997

Roche Terminates Tenefuse For RA

16 October 1997

Periostat Filed In First European Market

24 July 1997

Connetics' Pipeline A Credit To 4-Year-Old Firm

23 July 1997

Biospecifics Link-Up With B&L

26 June 1997

Collagenase Cuts Scarring In Ph I Trial

3 March 1997

FDA Panel Rejects Pfizer's Tenidap Application

13 May 1996

Xenova "Outstanding Long-Term Investment"

15 August 1994

AFFYMAX EXPANDS DRUG SCREENING CAPACITY

1 November 1993

XENOVA AND FMC CORP IN LINK-UP

11 October 1993

XENOVA IN CLINIC WITHIN 12 TO 18 MONTHS?

8 March 1993

Showing 1-28 of 28 articles

Go to beginningPrevious
  • 1
NextGo to end